During a recent meeting of the FDAs Pharmacy Compounding Advisory Committee, seven peptides with what FDA scientists deemed limited to no evidence of efficacy in human trials will be reviewed for potential use in conditions like ulcerative colitis, migraines, wound healing, inflammatory conditions, obesity, insomnia, osteoporosis and more
[1] [2] While Ozempic may produce weight loss as a pharmacological effect, it is specifically licensed for type 2 diabetes management in the UK, not for weight management
The Study Has Some Limitations The study design comparing people to themselves over time helps reduce some variables among participants that can make findings inconclusive, says Dr
Most common side effect for both peptides
Both are excellent options